Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Gilead fell $0.75 (-1.0%) to $74.45 on light volume. Throughout the day, 4,877,472 shares of Gilead exchanged hands as compared to its average daily volume of 10,595,500 shares. The stock ranged in price between $74.25-$75.36 after having opened the day at $75.36 as compared to the previous trading day's close of $75.20. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 39.8%,

Coronado Biosciences



), down 9.5%,

Tekmira Pharmaceuticals Corporation



TheStreet Recommends

), down 6.8% and

Hyperion Therapeutics



), down 6.4%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $114.9 billion and is part of the health care sector. Shares are up 104.8% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front,




), up 16.0%,

Merus Labs International



), up 14.6%,

Cardium Therapeutics



), up 13.9% and

CytRx Corporation



), up 13.8% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.